# A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

> **NCT06040099** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 58 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Bevacizumab
- **PROCEDURE:** Transarterial Radioembolization (TARE)

## Key facts

- **NCT ID:** NCT06040099
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-13
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06040099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06040099, "A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06040099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*